Advertising

Aptose Biosciences

APS-T

Analysis and Opinions about APS-T

Signal
Opinion
Expert
Chart
PARTIAL BUY
PARTIAL BUY
July 5, 2019
Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.
Show full opinionHide full opinion
Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.
RISKY BUY
RISKY BUY
April 21, 2014

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

Show full opinionHide full opinion

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

Fabrice Taylor
Price
$0.540
Owned
Unknown
SELL
SELL
November 17, 2005
At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.
Show full opinionHide full opinion
Aptose Biosciences (APS-T)
November 17, 2005
At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.
Peter Hodson
Price
$0.285
Owned
Unknown
BUY
BUY
September 29, 2005
A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.
Show full opinionHide full opinion
Aptose Biosciences (APS-T)
September 29, 2005
A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.
Robert Floyd
Price
$0.670
Owned
Yes
BUY
BUY
June 28, 2004
One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.
Show full opinionHide full opinion
One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.
Robert Floyd
Price
$0.840
Owned
Yes
DON'T BUY
DON'T BUY
June 1, 2004
Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.
Show full opinionHide full opinion
Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.
Robert Floyd
Price
$0.860
Owned
Yes
WEAK BUY
WEAK BUY
April 19, 2004
Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.
Show full opinionHide full opinion
Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.
Hugh McCauley
Price
$1.060
Owned
Yes
DON'T BUY
DON'T BUY
December 9, 2003
Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.
Show full opinionHide full opinion
Aptose Biosciences (APS-T)
December 9, 2003
Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.
Lou Schizas
Price
$1.040
Owned
Unknown
BUY
BUY
December 8, 2003
A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.
Show full opinionHide full opinion
Aptose Biosciences (APS-T)
December 8, 2003
A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.
Robert Floyd
Price
$1.070
Owned
Yes
BUY
BUY
September 22, 2003
Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.
Show full opinionHide full opinion
Aptose Biosciences (APS-T)
September 22, 2003
Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.
Robert Floyd
Price
$1.290
Owned
Yes
DON'T BUY
DON'T BUY
August 20, 2003
High-risk company.You should own five or six in this sector in order to spread the risks.
Show full opinionHide full opinion
High-risk company.You should own five or six in this sector in order to spread the risks.
BUY WEAKNESS
BUY WEAKNESS
July 21, 2003
Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.
Show full opinionHide full opinion
Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.
BUY
BUY
July 4, 2003
Just did a financing to extend development on new products. Sees further improvement.
Show full opinionHide full opinion
Just did a financing to extend development on new products. Sees further improvement.
Robert Floyd
Price
$1.250
Owned
Yes
DON'T BUY
DON'T BUY
June 24, 2003
Has never generated any degree of profitability. Speculative.
Show full opinionHide full opinion
Has never generated any degree of profitability. Speculative.
BUY
BUY
May 14, 2003
Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one.
Show full opinionHide full opinion
Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one.
John Sinkins, CFA
Price
$1.410
Owned
Unknown
Showing 1 to 15 of 44 entries

Aptose Biosciences(APS-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Aptose Biosciences is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Aptose Biosciences(APS-T) Frequently Asked Questions

What is Aptose Biosciences stock symbol?

Aptose Biosciences is a Canadian stock, trading under the symbol APS-T on the Toronto Stock Exchange (APS-CT). It is usually referred to as TSX:APS or APS-T

Is Aptose Biosciences a buy or a sell?

In the last year, there was no coverage of Aptose Biosciences published on Stockchase.

Is Aptose Biosciences a good investment or a top pick?

Aptose Biosciences was recommended as a Top Pick by Hap (Robert) Sneddon FCSI on 2019-07-05. Read the latest stock experts ratings for Aptose Biosciences.

Why is Aptose Biosciences stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Aptose Biosciences worth watching?

0 stock analysts on Stockchase covered Aptose Biosciences In the last year. It is a trending stock that is worth watching.

What is Aptose Biosciences stock price?

On 2021-08-04, Aptose Biosciences (APS-T) stock closed at a price of $3.25.